Quick-Med Technologies, Inc.

Company Overview

August, 2009

Forward-Looking Statements

This presentation contains forward-looking statements (statements which are not statements of historical facts). Any statements contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "expects", "plans", "believes", "anticipates", "intends", "estimates", or statements concerning potential opportunities or variations thereof or comparable terminology or the negative thereof should be construed as forward-looking statements involving risks and uncertainties, including without limitation the launch and approval of the potential products described herein and the Company's results of operations. The Company is also subject to other risks as detailed from time-to-time in the Company's SEC filings.

Company Overview

Quick-Med Technologies, Inc. is an innovative life sciences company

- Break-through technologies for the healthcare and consumer markets
- Development Center in Gainesville, Florida
- Publicly-traded (under the symbol "QMDT" on the OTC Bulletin Board)

Four Core Technologies

- *NIMBUS*® – a unique, non-leaching antimicrobial for use in a wide range of medical device applications
- *Stay Fresh*™ – a extraordinarily durable and effective antimicrobial technology for textiles
- *NimbuDerm*™ – a persistent skin sanitizer
- *MultiStat*® – a family of advanced patented compounds and methods shown to be highly effective in key skin care applications for medical and cosmetic markets

TIME
Microbe-Busting Bandages
Innovators Forging the Future

Wound Healing Society
Blue Ribbon Industrial R&D Awards
2006 , 2008-2 awards

Management Team

Ladd Greeno *Chief Executive Officer*	Joined in 2007. 30+ years of management and executive experience. Agion Technologies – CEO; Arthur D. Little – COO, SVP Management Consulting, SVP Environmental Consulting. MBA, Harvard Business School
Jerry Olderman, Ph.D *VP, Research & Development*	Joined in 1997. 45 years of healthcare, and R&D experience. C.R. Bard's Cardiopulmonary Division – Director of R&D; Baxter Healthcare – VP, R&D Pharmaseal Division; Surgikos Division of Johnson and Johnson, VP R&D. PhD, Physical Chemistry, Seton Hall
Nam Nguyen, CPA *Chief Financial Officer*	CFO since 2004. 24 years accounting experience. W. R. Grace – Mgr Financial Controls ; John Alden Financial Corporation – VP, Financial Reporting; PricewaterhouseCoopers – senior manager.
Roy Carr *Business Development*	Joined in 2005. 20 years experience in wound care and medical devices. Ferris Mfg Corp. (advanced wound care) – COO; Sterigenics –General Manager, RCMedical–Managing Partner. MS, Physical Chemistry and MBA, Illinois Institute of Technology

- Scientific Advisors
  - **Greg Schultz, Ph.D** – Professor of Obstetrics/Gynecology & Director of the Institute for Wound Research, College of Medicine, University of Florida. Past president, Wound Healing Society
  - **Chris Batich, Ph.D** – Professor of Materials Science and Engineering, University of Florida
- **Seven person scientific team** comprising post-doctoral experts in material science and engineering, polymer chemistry, and microbiology

Our Approach

- A high margin business with limited infrastructure—no manufacturing, no inventory carrying costs, expenses focused on R&D and business development
  - We *license* our technologies to leading organizations in key markets where the benefits of our patented innovations offer maximum value
  - Where appropriate, we will offer *exclusive "first-to-market" licensing agreements* by market segment
- We provide *highly experienced life scientists* to work with our customers to impart our technology to their products
- We *deliver* high-performance product innovations that enable our customers to address consumer needs at low cost and without significant capital investment

NIMBUS® *Unique FDA-Cleared Technology*

Problem

- Two million patients acquire hospital-related infections, annually
- This results in $7 billion in additional treatment and 90,000 deaths
- Resistant bacteria are increasingly being found in community settings
- Most antimicrobials
  - don't work in the presence of body fluids
  - must leach (deplete) to work
  - are susceptible to inducing bacterial resistance

Solution

NIMBUS® is a unique technology …

- Bonded, non-leaching, no migration from site to skin, not depleted in use
- Very large molecule, not blocked by blood, urine, perspiration
- Highly effective against MRSA with no bacterial resistance issues
- FDA "*de novo*" device— not a drug

…and is highly cost effective relative to other antimicrobials

NIMBUS® *Efficacy and Mode of Action*

Broad Spectrum Microbial Efficacy*

	ATCC#	% Reduction
Staphylococcus aureus	12600	>99.9999%
Escherichia coli	15597	>99.9999%
Klebsiella pneumoniae	13833	>99.9999%
Pseudomonas aeruginosa	51447	>99.9999%
Proteus vulgaris	13115	>99.9999%
Serratia marcescens	13880	>99.9999%
Enterococcus faecalis	19433	>99.9999%
Enterobacter aerogenes	13048	>99.9999%
Listeria monocytogenes	13932	>99.9999%
MRSA	BAA-44	>99.9999%
VRE	700221	>99.9994%
Bacteriophage MS-2 *(RNA virus)*		>99.994%
Bacteriophage PRD1 *(DNA virus)*		>99.87%

** Tested in 10% bovine serum (except viruses) after18 hours of exposure*

Cell Walls Collapse after NIMBUS Contact

Staphylococcus aureus



Before After

Escherichia coli



Before After

Rapid Kill Rate *even in high challenge environments**

Time	Staph. a.	E. Coli	Pseudo. A
1 min	99.98780 %	96.99842%	99.98205%
10 min	99.99415%	99.99763%	99.98564%
20 min	99.99268%	99.99938%	99.99397%
30 min	99.99878%	99.99972%	99.99746%
60 min	99.9999%	99.99946%	99.99936%

** Tested in 10% bovine serum*

NIMBUS *Competitive Comparison*

NIMBUS offers a superior performance, price and safety profile

Characteristic	NIMBUS	Silver	Triclosan	PHMB	Silane Quaternary
Effectiveness	**High**	High	Medium	Medium	Low
Persistence	**High**	Medium	Medium	Low	Low
Leaching	**No**	Yes	Yes	Yes	No
Resistance	**No**	Documented	Yes	Yes	No
Economics	**Low Cost**	Expensive	Medium Cost	Medium Cost	Medium Cost

Stay Fresh *Highly Durable Textiles Technology*

Need

- Textiles are reservoirs for bacteria
- Offensive odors result from the metabolism of perspiration on clothing
  - Intimate skin contact (essential wear)
  - Prolonged, stressful, or repeated wear (work wear, sports wear)
- Healthcare fabrics and work wear are vulnerable to pathogen contamination
- Most antimicrobial textile treatments
  - Don't sustain a high efficacy through repeated laundering
  - Release toxics to skin or environment
  - Can induce bacterial resistance

Solution

Stay Fresh™ is a breakthrough technology

- "Full kill" even after 50+ laundering cycles both Gram-positive and Gram-negative bacteria
- Highly effective against drug resistant bacteria
- Safe and environmental friendly. Contain no organic halogens such as Triclosan or PCBs.
- Effective even in cold-water laundering
- Superior performance and durability at lowest cost

EPA registration is underway and partners are currently being developed for

- Healthcare textiles
- Commercial uniforms
- Essential wear

Stay Fresh *Consumer Receptivity & Increasing Need*

Consumers are willing to pay a premium for clothing that stays fresher, longer[1]

- Nearly half (48%) - including more than half of male consumers (51%) - reported that they would be *willing to pay more* for clothing containing freshness-enhancing treatments
- The study found that the freshness-treated garments that men would be most interested in purchasing are shirts and tops (44 percent), socks (44 percent), and pants and slacks (42 percent)

Consumers have moved to short-cycle, cold-water washes to save energy and wear and tear on clothing, but this leaves bacteria and viruses largely intact[2]

- 140° F water will sanitize laundry. However, only 5 percent of consumers use hot water for laundry.
- Bacteria such as Salmonella and viruses such as hepatitis A, rotavirus - all of which cause stomach upsets and diarrhea - can easily survive the average 28-minute drying cycle. (All are all carried fecally.)

[1] Taylor Nelson Sofres, survey of 2,000 U.S. adults between the ages of 18 and 64 (Margin of error of one percent)

[2] Professor Charles Gerba, University of Arizona

NimbuDerm *Fulfilling a Critical Market Need*

Problem	• Hand contact with contaminated surfaces has been established as the primary way that individuals catch germs • A majority of people, including trained healthcare workers, simply do not wash their hands properly or as frequently as they should for good health
	• Hand sanitizers ($2 billion global sales) provide a brief reduction in germ counts on skin, but contact with surfaces returns germs to the skin • Contaminated surfaces are everywhere, even in hospitals where studies have found ~75% of all patient rooms have surfaces contaminated with MRSA • Problematic bacteria and viruses can survive on surfaces for multiple days
Solution	• NimbuDerm™ delivers a breakthrough in hand-hygiene technology—safe, effective, instant, and extraordinarily long-lasting antimicrobial protection • Reducing bacteria on hands and preventing infections before they develop contributes to good health, minimizes cost and risk, and saves lives

NimbuDerm *Overview*

A breakthrough in hand hygiene technology

NimbuDerm™

Assurance of germ-free hands

- Proprietary persistent antimicrobial film barrier
- Effectively kills pathogens immediately
- Remains on skin until removed by soap and water
- Continues to destroy microorganisms on contact for 6^{+} hours
- Has broad spectrum efficacy
- Immediate performance matches commercially available sanitizers (99.99% reduction) with increased performance of 99.9999% at four and six hours
- Can be formulated as a skin sanitizer liquid, spray, foam or wipe

MultiStat®

Commercialized as a Cosmeceutical

- Global Manufacturing and Distribution Agreement established with BASF
- Active ingredient in anti-aging creams, such as Patricia Wexler line of anti-aging creams (Bath & Body Works stores)

Government-Funded Research

- Incorporation in an advanced wound dressing
- Treatment of Sulfur Mustard injuries to eye and skin



MultiStat Reduces Neovascularization and Scar Formation in Rabbit Eyes Following Sulfur Mustard Exposure

MultiStat compounds are 1,000 times more effective than the natural MMPI's that are present in human blood and some plant extracts

Solid Patent Protection

Antimicrobial Technologies

- *NIMBUS*® – Two U.S. and seven foreign patents granted; seven U.S. and fifteen foreign patents pending
- *Stay Fresh*™ – Two U.S. patents pending
- *NimbuDerm*™ – Two U.S. and nine foreign patents pending

Unlike silver or other antimicrobials, Quick-Med's antimicrobial technologies are protected from competitive threats by long-lived patents.

MMPI Technology

- Ten U.S. patents and foreign counterparts granted
- Four U.S patents pending

Broad Applications

NIMBUS

- ✓ Traditional and advanced wound care
- ✓ Catheters and sutures
- ✓ Diapers and incontinence products
- ✓ Feminine hygiene
- ✓ Adhesives

Stay Fresh

- ✓ Medical textiles: surgical gowns, scrubs, bed linens
- ✓ Apparel: essential wear, active wear, and work wear
- ✓ Bed linens

NimbuDerm

- ✓ Persistent hand sanitizers
- ✓ Antimicrobial wipes

MultiStat

- ✓ Skin care
- ✓ Advanced wound care

Highlights

- Unique and cost-effective technologies
- Solid patent protection
- Large market opportunities with little effective competition
- Broad application across medical devices and consumer healthcare
- Near-term catalysts
- High margin business model, with low infrastructure needs
- Outstanding scientific and research teams

Quick-Med
Technologies, Inc.

Developing Next Generation Technologies and Beyond